Abstract:
The human T-cell leukemia viruses (HTLV) I and II, have been implicated in naturally occurring T-cell malignancies in man. We are engaged in ongoing comparative studies of HTLV-I and HTLV-II in our laboratory. We have isolated a replication-competent clone of HTLV-II, as well as several defective HTLV-II proviruses from the Mo-T hairy-cell leukemia line. HTLV-II is able to transform normal T-lymphocytes, and can replicate in both T- and B-cell lines. We have devised a convenient system allowing direct transfection of the HTLV-II genome into a B-cell line, followed by selection of HTLV-infected cells. Transfection studies with HTLV-II indicate that the virus can replicate in lymphoid cells, but not in fibroblasts. Transfection of recombinant constructs demonstrates that the viral long terminal repeat (LTR) can function as a promoter in lymphoid cells, but not in fibroblasts, suggesting a role for the viral LTR in conferring target cell specificity. Structural similarities between the HTLV-I and HTLV-II LTRs, including the presence of similar repeated base sequences in the U3 region, may account for this LTR specificity. The X region of HTLV-II has been sequenced and compared to that of HTLV-I. We have identified an mRNA species encoded by the major open reading frames in the X region of HTLV-I and HTLV-II and have located the splice acceptor site. Using antisera generated to short peptide sequences encoded by X, we have identified specific X-encoded viral proteins in HTLV infected cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Cell Transformation, Neoplastic Cell Transformation, Viral Cloning, Molecular Comparative Study *Genes, Viral HTLV-BLV Viruses/*GENETICS Repetitive Sequences, Nucleic Acid Transfection JOURNAL ARTICLE REVIEW
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.
